China’s Gan & Lee Soars After Selling Rights to Weight Loss Drug in Europe to Menarini for USD839 MillionYicai·Aug 11 at 03:26 AM603087-4.79%
Gan & Lee Pharmaceuticals Wins Honduras Drug Registration for Vitaglar Insulin Glargine Prefilled PenCoinLive·Jul 9 at 04:07 AM603087-4.79%
Gan & Lee Pharmaceuticals Achieves Significant Progress in Its Dual Pipeline for Metabolic Diseases — Weekly Insulin Ludefen (GZR4) Meets Primary Endpoint in Phase III Clinical Trial in China; Bofanglutide Meets Primary Endpoints in Phase III Weight Loss Study in China and Phase II Study in the U.S.MorningStar·Jun 12 at 07:17 AM603087-4.79%
From basic to enhanced, Gan & Lee's GZR4 third item III phase study has met the standards同壁财经·Jun 8 at 09:50 PM603087-4.79%
Gan & Lee Pharmaceuticals' commercialization layout in the Brazilian market has made further progress, achieving dual compliance from raw materials to formulations同壁财经·May 26 at 09:09 AM603087-4.79%
